Modulation of the inflammatory response for enhanced bone tissue regeneration

Tissue Engineering - Part B: Reviews

Volumn 14, Issue 2, 2008, Pages 179-186

  Mountziaris, Paschalia M ^a   Mikos, Antonios G ^a  

^a Rice University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL DEVICES; BONE REGENERATION; BONE TISSUE REGENERATION; FRACTURE HEALING; INFLAMMATORY DISEASES; INFLAMMATORY RESPONSES; PHARMACOLOGIC AGENTS; PRO INFLAMMATORY CYTOKINES; TISSUE REGENERATION;

ARCHITECTURAL DESIGN; BONE; FRACTURE FIXATION; HEALTH; MODULATION; STABILIZERS (AGENTS); TECHNOLOGY; TISSUE CULTURE; TISSUE ENGINEERING;

TISSUE;

ADALIMUMAB; ANTIINFLAMMATORY AGENT; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; ETANERCEPT; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INDOMETACIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROFECOXIB; TP 508; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VALDECOXIB;

ARTHRITIS; BONE DEVELOPMENT; BONE NECROSIS; BONE REGENERATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHONDROGENESIS; FRACTURE; FRACTURE HEALING; GENE MUTATION; HUMAN; INFLAMMATION; NONHUMAN; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; STEM CELL; TISSUE ENGINEERING;

ANTI-INFLAMMATORY AGENTS; BONE REGENERATION; FRACTURES, BONE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION MEDIATORS; OSTEITIS; SIGNAL TRANSDUCTION; TISSUE ENGINEERING; WOUND HEALING;

EID: 45249115763     PISSN: 19373368     EISSN: None     Source Type: Journal    
DOI: 10.1089/ten.teb.2008.0038     Document Type: Review

References (78)

1. Freed, L.E., Guilak, F., Guo, X.E., Gray, M.L., Tranquillo, R., Holmes, J.W., Radisic, M., Sefton, M.V., Kaplan, D., and Vunjak-Novakovic, G. Advanced tools for tissue engineering: scaffolds, bioreactors, and signaling. Tissue Eng 12, 3285, 2006.
2. Langer, R., and Tirrell, D.A. Designing materials for biology and medicine. Nature 428, 487, 2004.
3. Rundle, C.H., Wang, H., Yu, H., Chadwick, R.B., Davis, E.I., Wegedal, J.E., Lau, K.-H.W., Mohan, S., Ryaby, J.T., and Baylink, D.J. Microarray analysis of gene expression during the inflammation and endochondral bone formation stages of rat femur fracture repair. Bone 38, 521, 2006.
4. Hecht, J., Kuhl, H., Haas, S.A., Bauer, S., Poustka, A.J., Lienau, J., Schell, H., Stiege, A.C., Seitz, V., Reinhardt, R., Duda, G.N., Mundolos, S., and Robinson, P.N. Gene identification and analysis of transcripts differentially regulated in fracture healing by EST sequencing in the domestic sheep. BMC Genomics 7, 172, 2006.
5. Ingber, D.E., Mow, V.C., Butler, D., Niklason, L., Huard, J., Mao, J., Yannas, I., Kaplan, D., and Vunjak-Novakovic, G. Tissue engineering and developmental biology: going biomimetic. Tissue Eng 12, 3265, 2006.
6. Filbin, M.T. How inflammation promotes regeneration. Nat Neurosci 9, 715, 2006.
7. Lumelsky, N.L. Commentary: engineering of tissue healing and regeneration. Tissue Eng 13, 1393, 2007.
8. Dimitriou, R., Tsiridis, E., and Giannoudis, P.V. Current concepts of molecular aspects of bone healing. Injury 36, 1392, 2005.
9. Einhorn, T.A. The cell and molecular biology of fracture healing. Clin Orthop Relat Res 355 (Suppl), S7, 1998.
10. Cho, T.-J., Gerstenfeld, L.C., and Einhorn, T.A. Differential temporal expression of members of the transforming growth factor β superfamily during murine fracture healing. J Bone Miner Res 17, 513, 2002.
11. Gerstenfeld, L.C., Cullinane, D.M., Barnes, G.L., Graves, D.T., and Einhorn, T.A. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem 88, 873, 2003.
12. Sfeir, C., Ho, L., Doll, B.A., Azari, K., and Hollinger, J.O. Fracture repair. In: Lieberman, J.R., and Friedlaender, G.E., eds. Bone Regeneration and Repair. Totowa, NJ: Humana Press, 2005, pp. 21-44.
13. Lieberman, J.R., Daluiski, A., and Einhorn, T.A. The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am 84-A, 1032, 2002.
14. Doll, B.A., Sfeir, C., Azari, K., Holland, S., and Hollinger, J.O. Craniofacial repair. In: Lieberman, J.R., and Friedlaender, G.E., eds. Bone Regeneration and Repair. Totowa, NJ: Humana Press, 2005, pp. 337-358.
15. Barnes, G.L., Kostenuik, P.J., Gerstenfeld, L.C., and Einhorn, T.A. Growth factor regulation of fracture repair. J Bone Miner Res 14, 1805, 1999.
16. Andreassen, T.T., and Oxlund, H. Local anabolic effects of growth hormone on intact bone and healing fractures in rats. Calcif Tissue Int 73, 258, 2003.
17. Bail, H.J., Kolbeck, S., Krummrey, G., Schmidmaier, G., Haas, N.P., and Raschke, M.J. Systemic application of growth hormone for enhancement of secondary and intramembranous fracture healing. Horm Res 58 (Suppl 3), 39, 2002.
18. Andreassen, T.T., Ejersted, C., and Oxlund, H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 14, 960, 1999.
19. Nakajima, A., Shimoji, N., Shiomi, K., Shimizu, S., Moriya, H., Einhorn, T.A., and Yamazaki, M. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res 17, 2038, 2002.
20. Yu-Yahiro, J.A., Michael, R.H., Dubin, N.H., Fox, K.M., Sachs, M., Hawkes, W.G., Hebel, J.R., Zimmerman, S.I., Shapiro, J., and Magaziner, J. Serum and urine markers of bone metabolism during the year after hip fracture. J Am Geriatr Soc 49, 877, 2001.
21. Veitch, S.W., Findlay, S.C., Hamer, A.J., Blumsohn, A., Eastell, R., and Ingle, B.M. Changes in bone mass and bone turnover following tibial shaft fracture. Osteoporos Int 17, 364, 2006.
22. Ingle, B.M., Hay, S.M., Bottjer, H.M., and Eastell, R. Changes in bone mass and bone turnover following ankle fracture. Osteoporos Int 10, 408, 1999.
23. Ivaska, K.K., Gerdhem, P., Kesson, K., Garnero, P., and Obrant, K.J. Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res 22, 1155, 2007.
24. Obrant, K.J., Ivaska, K.K., Gerdhem, P., Alatalo, S.L., Pettersson, K., and Vaananen, H.K. Biochemical markers of bone turnover are influenced by recently sustained fracture. Bone 36, 786, 2005.
25. Miclau, T., Schneider, R.A., Eames, B.F., and Helms, J.A. Common molecular mechanisms regulating fetal bone formation and adult fracture repair. In: Lieberman, J.R., and Friedlaender, G.E., eds. Bone Regeneration and Repair. Totowa, NJ: Humana Press, 2005, pp. 45-55.
26. Luttikhuizen, D.T., Harmsen, M.C., and van Luyn, M.J.A. Cellular and molecular dynamics in the foreign body reaction. Tissue Eng 12, 1955, 2006.
27. Romas, E., Gillespie, M.T., and Martin, T.J. Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis. Bone 30, 340, 2002.
28. Glasson, S. Identification of targets through histologic evaluation of osteoarthritis in knock out mice. Osteoarthritis Cartilage 13 (Suppl A), S3, 2005.
29. Martin, P., D'Souza, D., Martin, J., Grose, R., Cooper, L., Maki, R., and McKercher, S.R. Wound healing in the PU.1 null mouse - tissue repair is not dependent on inflammatory cells. Curr Biol 13, 1122, 2003.
30. Tsiridis, E., Upadhyay, N., and Giannoudis, P.V. Molecular aspects of fracture healing: which are the important molecules? Injury 38 (Suppl 1), S11, 2007.
31. Locksley, R.M., Killeen, N., and Lenardo, M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487, 2001.
32. Kon, T., Cho, T.-J., Aizawa, T., Yamazaki, M., Nooh, N., Graves, D.T., Gerstenfeld, L.C., and Einhorn, T.A. Expression of osteoprotegerin, receptor activator of NF-κB ligand (osteoprotegrin ligand) and related pro-inflammatory cytokines during fracture healing. J Bone Miner Res 16, 1004, 2001.
33. Gerstenfeld, L.C., Cho, T.-J., Kon, T., Aizawa, T., Tsay, A., Fitch, J., Barnes, G.L., Graves, D.T., and Einhorn, T.A. Impaired fracture healing in the absence of TNF-α signaling: the role of TNF-α in endochondral cartilage resorption. J Bone Miner Res 18, 1584, 2003.
34. Cho, H.H., Bae, Y.C., and Jung, J.S. Role of toll-like receptors on human adipose-derived stromal cells. Stem Cells 24, 2744, 2006.
35. Nanes, M.S., and Pacifici, R. Inflammatory cytokines. In: Bronner, F., Farach-Carson, M.C., and Rubin, J., eds. Bone Resorption. New York, NY: Springer, 2005, pp. 67-90.
36. Balga, R., Wetterwald, A., Portenier, J., Dolder, S., Mueller, C., and Hofstetter, W. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro. Bone 39, 325, 2006.
37. Lee, S.-K., and Lorenzo, J.A. Cytokines regulating osteoclast formation and function. Curr Opin Rheumatol 18, 411, 2006.
38. Bajayo, A., Goshen, I., Feldman, S., Csernus, V., Iverfeldt, K., Shohami, E., Yirmiya, R., and Bab, I. Central IL-1 receptor signaling regulates bone growth and mass. Proc Natl Acad Sci USA 102, 12956, 2005.
39. Yang, X., Ricciardi, B.F., Hernandez-Soria, A., Shi, Y., Camacho, N.P., and Bostrom, M. Callus mineralization and maturation are delayed during fracture healing in interleukin-6 knockout mice. Bone 41, 928, 2007.
40. Miller, R.R., Cappola, A.R., Shardell, M.D., Hawkes, W.G., Yu-Yahiro, J.A., Hebel, J.R., and Magaziner, J. Persistent changes in interleukin-6 and lower extremity function following hip fracture. J Gerontol A Biol Sci Med Sci 61, 1053, 2006.
41. Pape, H.-C., Schmidt, R.E., Rice, J., van Griensven, M., das Gupta, R., Krettek, C., and Tscherne, H. Biochemical changes after trauma and skeletal surgery of the lower extremity: quantification of the operative burden. Crit Care Med 28, 3441, 2000.
42. Lewis, D.B., Liggitt, H.D., Effmann, E.L., Motley, S.T., Teitelbaum, S.L., Jepsen, K.J., Goldstein, S.A., Bonadio, J., Carpenter, J., and Perlmutter, R.M. Osteoporosis induced in mice by overproduction of interleukin 4. Proc Natl Acad Sci USA 90, 11618, 1993.
43. Macias, M.P., Fitzpatrick, L.A., Brenneise, I., McGarry, M.P., Lee, J.J., and Lee, N.A. Expression of IL-5 alters bone metabolism and induces ossification of the spleen in transgenic mice. J Clin Invest 107, 949, 2001.
44. Horwood, N.J., Elliott, J., Martin, T.J., and Gillespie, M.T. IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol 166, 4915, 2001.
45. Nagata, N., Kiataura, H., Yoshida, N., and Nakayama, K. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population. Bone 33, 721, 2003.
46. Kawase, Y., Hoshino, T., Yokota, K., Kuzuhara, A., Nakamura, M., Maeda, Y., Nishiwaki, E., Zenmyo, M., Hiraoka, K., Aizawa, H., and Yoshino, K. Bone malformations in interleukin-18 transgenic mice. J Bone Miner Res 18, 975, 2003.
47. Gowen, M., MacDonald, B.R., and Russell, R.G. Actions of recombinant human gamma-interferon and tumor necrosis factor alpha on the proliferation and osteoblastic characteristics of human trabecular bone cells in vitro. Arthritis Rheum 31, 1500, 1988.
48. Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., Takaoka, A., Yokochi, T., Oda, H., Tanaka, K., Nakamura, K., and Taniguchi, T. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 408, 600, 2000.
49. Mann, G.N., Jacobs, T.W., Buchinsky, F.J., Armstrong, E.C., Li, M., Ke, H.Z., Ma, Y.F., Jee, W.S.S., and Epstein, S. Interferon-gamma causes loss of bone volume in vivo and fails to ameliorate cyclosporin A-induced osteopenia. Endocrinology 135, 1077, 1994.
50. Aspenberg, P. Drugs and fracture repair. Acta Orthop 76, 741, 2005.
51. Goodman, S.B., Jiranek, W., Petrow, E., and Yasko, A.W. The effects of medications on bone. J Am Acad Orthop Surg 15, 450, 2007.
52. Pieringer, H., Stuby, U., and Biesenbach, G. Patients with rheumatoid arthritis undergoing surgery: how should we deal with anti-rheumatic treatment? Semin Arthritis Rheum 36, 278, 2007.
53. Li, X., Wang, H., Touma, E., Qi, Y., Rousseau, E., Quigg, R.J., and Ryaby, J.T. TP508 accelerates fracture repair by promoting cell growth over cell death. Biochem Biophys Res Commun 364, 187, 2007.
54. Wang, H., Li, X., Tomin, E., Doty, S.B., Lane, J.M., Carney, D.H., and Ryaby, J.T. Thrombin peptide (TP508) promotes fracture repair by up-regulating inflammatory mediators, early growth factors, and increasing angiogenesis. J Orthop Res 23, 671, 2005.
55. Sheller, M.R., Crowther, R.S., Kinney, J.H., Yang, J., Di Jorio, S., Breunig, T., Carney, D.H., and Ryaby, J.T. Repair of rabbit segmental defects with the thrombin peptide, TP508. J Orthop Res 22, 1094, 2004.
56. Hedberg, E.L., Kroese-Deutman, H.C., Shih, C.K., Crowther, R.S., Carney, D.H., Mikos, A.G., and Jansen, J.A. Effect of varied release kinetics of the osteogenic thrombin peptide TP508 from biodegradable, polymeric scaffolds on bone formation in vivo. J Biomed Mater Res A 72, 343, 2005.
57. Fife, C., Mader, J.T., Stone, J., Brill, L., Satterfield, K., Norfleet, A., Zwernemann, A., Ryaby, J.T., and Carney, D.H. Thrombin peptide Chrysalin(R) stimulates healing of diabetic foot ulcers in a placebo-controlled phase I/II study. Wound Repair Regen 15, 23, 2007.
58. Ho, M.L., Chang, J.K., and Wang, G.J. Antiinflammatory drug effects on bone repair and remodeling in rabbits. Clin Orthop Relat Res 313, 270, 1995.
59. Lyritis, G., Papadopoulou, Z., Nikiforidis, P., Batrinos, M., and Varonos, D. Effects of cortisone and anabolic steroid upon plasma hydroxyproline during fracture healing in rabbits. Acta Orthop Scand 1975, 25, 1975.
60. Waters, R.V., Gamradt, S.C., Asnis, P., Vickery, B.H., Avnur, Z., Hill, E., and Bostrom, M. Systemic corticosteroids inhibit bone healing in a rabbit ulnar osteotomy model. Acta Orthop Scand 71, 316, 2000.
61. Jaiswal, N., Haynesworth, S.E., Caplan, A.I., and Bruder, S.P. Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. J Cell Biochem 64, 295, 1997.
62. Haisch, A., Wanjura, F., Radke, C., Leder-Johrens, K., Groger, A., Endres, M., Klaering, S., Loch, A., and Sittinger, M. Immunomodulation of tissue-engineered transplants: in vivo bone generation from methylprednisolone-stimulated chondrocytes. Eur Arch Otorhinolaryngol 261, 216, 2004.
63. Orwin, J.F. Use of the uncemented bipolar endoprosthesis for the treatment of steroid-induced osteonecrosis of the hip in renal transplantation patients. J Arthroplasty 6, 1, 1991.
64. Brantus, J.F., and Meunier, P.J. Effects of intravenous etidronate and oral corticosteroids in fibrodysplasia ossificans progressiva. Clin Orthop Relat Res 346, 117, 1998.
65. Kaplan, F.S., Shore, E.M., Glaser, D.L., and Emerson, S. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Clin Proc Intl Clin Consort FOP 1, 1, 2005.
66. Vuolteenaho, K., Moilanen, T., and Moilanen, E. Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process. Basic Clin Pharmacol Toxicol 102, 10, 2007.
67. Gerstenfeld, L.C., Thiede, M.A., Seibert, K., Mielke, C., Phippard, D., Svagr, B., Cullinane, D.M., and Einhorn, T.A. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J Orthop Res 21, 670, 2003.
68. Simon, A.M., Manigrasso, M.B., and O'Connor, J.P. Cyclooxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 17, 963, 2002.
69. Zhang, X., Schwarz, E.M., Young, D.A., Puzas, J.E., Rosier, R.N., and O'Keefe, R.J. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 109, 1405, 2002.
70. Simon, A.M., and O'Connor, J.P. Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture healing. J Bone Joint Surg Am 89, 500, 2007.
71. Gerstenfeld, L.C., Al-Ghawas, M., Alkhiary, Y.M., Cullinane, D.M., Krall, E.A., Fitch, J.L., Webb, E.G., Thiede, M.A., and Einhorn, T.A. Selective and nonselective cyclooxygenase-2 inhibitors and experimental fracture-healing. J Bone Joint Surg Am 89, 114, 2007.
72. Giannoudis, P.V., MacDonald, D.A., Matthews, S.J., Smith, R.M., Furlong, A.J., and de Boer, P. Nonunion of the femoral diaphysis. The influence of reaming and non-steroidal antiinflammatory drugs. J Bone Joint Surg Br 82, 655, 2000.
73. Bhattacharyya, T., Levin, R., Vrahas, M.S., and Solomon, D.H. Nonsteroidal antiinflammatory drugs and nonunion of humeral shaft fractures. Arthritis Rheum 53, 364, 2005.
74. Neal, B.C., Rodgers, A., Clark, T., Gray, H., Reid, I.R., Dunn, L., and MacMahon, S.W. A systematic survey of 13 randomized trials of non-steroidal anti-inflammatory drugs for the prevention of heterotopic bone formation after major hip surgery. Acta Orthop Scand 71, 122, 2000.
75. Burd, T.A., Hughes, M.S., and Anglen, J.O. Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone nonunion. J Bone Joint Surg Br 85, 700, 2003.
76. Clyman, R.I. Ibuprofen and patent ductus arteriosus. N Engl J Med 343, 728, 2000.
77. Paralkar, V.M., Borovecki, F., Ke, H., Cameron, K.O., Lefker, B., Grasser, W.A., Owen, T.A., Li, M., DaSilva-Jardine, P., Zhou, M., Dunn, R.L., Dumont, F., Korsmeyer, R., Krasney, P., Brown, T.A., Plowchalk, D., Vukicevic, S., and Thompson, D.D. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci USA 100, 6736, 2003.
78. Tanaka, M., Sakai, A., Uchida, S., Tanaka, S., Nagashima, M., Katayama, T., Yamaguchi, K., and Nakamura, T. Prostaglandin E2 receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature rats. Bone 34, 940, 2004.